Short answer
Absci Corp (ABSI) filed an 8-K current report with the SEC on June 24, 2026 reporting Item 8.01 (Other Events), Item EX-99.1 (Exhibit EX-99.1). Interim Phase 1 data released for ABS-201 in the HEADLINE™ trial.
Absci Corp 8-K event analysis
AI summary of each reported item and its exhibits
Item 8.01 · Other Events
- Interim Phase 1 data released for ABS-201 in the HEADLINE™ trial
- Clinical update creates a potential valuation catalyst for Absci’s drug-development pipeline
- Full efficacy and safety details available in Exhibit 99.1.linkedin
Item EX-99.1 · Exhibit EX-99.1
- Positive Phase 1 safety signal: 32 participants across 150–1800 mg SAD cohorts, with no serious adverse events
- ABS-201 half-life estimated at least 65 days, supporting potential two- or three-dose administration over six months
- MAD dosing initiated in androgenetic alopecia participants, advancing the program toward efficacy assessment
- Interim proof-of-concept data expected second half 2026, with full results anticipated early 2027
- Early data remain blinded and interim, leaving efficacy, durability, and regulatory viability unproven
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Absci Corp 8-K filings
Get the next ABSI 8-K as it lands
Follow ABSI for push alerts, or ask the research agent what this filing means.